BrainLat UAI

What BrainLat UAI does

BrainLat UAI (Instituto BrainLat) is the Latin American Brain Health Institute, established in April 2021 within the Universidad Adolfo Ibáñez in Santiago, Chile, and co-directed by Agustín Ibáñez and Claudia Durán-Aniotz. The institute runs an interdisciplinary research program spanning brain aging, dementia, neurodegeneration, genetics, exposome analysis, and cognitive neuroscience, with a deliberate regional focus on Latin American populations historically underrepresented in global dementia research. Its scientific footprint includes the NIH-funded ReDLat consortium (one of the largest dementia research initiatives in Latin America), the LAC-CD network, and Epi-BrainNet, alongside high-impact publications in Nature Medicine and Nature Aging documenting validated blood biomarkers across six Latin American countries.

The institute's product portfolio centers on two AI-driven assets: BMindTune, a digital platform that estimates brain biological age from validated aging clocks and generates personalized recommendations across sleep, physical activity, social interaction, and cognitive health, and Neureka LATAM, a mobile application for self-administered neurocognitive assessment developed under Chile's ANID FONDEF program. Supporting outputs include the "Crónicas de un cerebro saludable" podcast, international training programs (sponsored by IDB and Argentina's Ministry of Education), and a publications pipeline through Frontiers in Aging Neuroscience. Capability is anchored by a team of Clarivate Highly Cited Researchers and recipients of the Premio RAICES and Nature Healthspan Accelerator Award.

Commercially, BrainLat UAI is structured as a non-commercial academic research institute operating under Universidad Adolfo Ibáñez rather than as a venture-backed company. Its revenue mechanics are grant-driven, drawing on competitive funding from ANID/FONDEF, the US National Institutes of Health, the Alzheimer's Drug Discovery Foundation, Target ALS, Horizon Europe (CLICBrain), and the Inter-American Development Bank. The go-to-market motion is event-driven — academic conferences (AAIC, BrainModes), webinars, scientific publications, fellowships, and community events — with a 5,000-member BMindTune pilot representing the institute's first sizable direct-to-user engagement.

Name

BrainLat UAI

Legal name

BrainLat Institute (Instituto BrainLat)

Website

https://brainlat.uai.cl

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

BrainLat UAI is the Latin American Brain Health Institute at Universidad Adolfo Ibáñez in Chile, conducting AI-driven research on brain aging, dementia biomarkers, and neurodegeneration across Latin America via the ReDLat consortium, BMindTune platform, and Neureka LATAM mobile app.

Ownership category

akta.pro rank

Product category

Neuroscience Research

NAICS

Research and Development in the Social Sciences and Humanities (54172)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

akta.pro secondary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Brain health research
• Dementia research
• Neurodegenerative disease studies
• Cognitive aging research
• Brain aging biomarkers

Headquarters

HQ city

Las Condes

HQ country

Chile

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Research Grants and Funding: As an academic institute, BrainLat UAI operates primarily through competitive research grants from government agencies (ANID/FONDEF, NIH) and international organizations. No commercial revenue model is applicable.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

BrainLat UAI is an academic research institute that conducts interdisciplinary brain health and dementia research with a Latin American focus, developing AI-driven tools such as the BMindTune brain aging platform and the Neureka LATAM mobile neurocognitive assessment app, and validating region-specific blood biomarkers for dementia diagnosis. Its core deliverables are research outputs (publications, validated biomarkers, aging clocks) and AI/mobile tools that translate scientific findings into accessible brain health measurement and dementia prevention products.

Product overview

BrainLat UAI is a research institute at Universidad Adolfo Ibáñez that functions as the Latin American Brain Health Institute, operating as a platform that combines multiple products and initiatives. The core offerings include BMindTune (an AI-powered brain aging measurement platform using aging clocks), Neureka LATAM (a mobile neurocognitive assessment application for dementia diagnosis), and the podcast 'Crónicas de un cerebro saludable' for public education. The institute conducts interdisciplinary research, provides training programs, and maintains international collaborations with the Global Brain Health Institute, Trinity College Dublin, and various research consortia including ReDLat and LAC-CD.

Differentiator

Problem solved

Functional benefit

Brands

• Neureka LATAM: A mobile application for self-administered neurocognitive assessment for dementia diagnosis in Chilean older adult population, developed under project ANID FONDEF IDeA I+D 22I10029.
• BMindTune
• ReDLat
• Epi-BrainNet

Products and services

• BMindTune AI-powered digital platform that measures brain biological age using scientifically validated aging clocks, comparing it to chronological age and providing personalized recommendations for brain health dimensions including sleep, physical activity, social interaction, and cognitive health; built on studies with 160,000+ participants and evidence published in Nature Medicine and Nature Aging.
• Neureka LATAM Mobile application for self-administered neurocognitive evaluation designed to support dementia diagnosis in the Chilean older adult population, developed under the ANID FONDEF IDeA I+D 22I10029 project with international collaborators including GERO, Altoida, and PRODEO Brain.

Quantifiable outcome

• BMindTune platform pilot: 5,000 members for first implementation
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

16 partnerships are on record, tiered major, core and minor.

• Universidad de Chile and Clínica MEDSmajorStrategic or Co-development Partner · 1 January 2026FONDEF-funded project to develop AI platform on menopause, reproductive history, and dementia risk.
• Epi-BrainNetmajorStrategic or Co-development Partner · 1 January 2025Latin American network on epigenetics and brain health. First Latin American meeting hosted in Punta Arenas, Chile, October 2025. Funded by Horizon Europe CLICBrain project.
• LAC-CD (Latin American and Caribbean Consortium on Dementia)coreStrategic or Co-development Partner · 1 January 2022Regional consortium focused on dementia research updates, webinars, and collaborative projects including ISTAART partnership. Key partner for Alzheimer's Association activities in Latin America.
• Alzheimer's Drug Discovery Foundation (ADDF) and Target ALSmajorStrategic or Co-development Partner · 1 January 2022International foundations providing funding for accelerated diagnosis and characterization of Alzheimer's disease, frontotemporal dementia, and ALS in Latin American populations.
• ANID-NAM (National Agency for Research and Development - National Academy of Medicine)majorStrategic or Co-development Partner · 1 January 2022ANID-NAM 2022 Global Healthy Longevity Challenge project on Alzheimer's disease treatment through blood-borne components from pregnant females.
• Trinity College DublinmajorStrategic or Co-development Partner · 1 January 2022Collaboration for Neureka LATAM app development, digital health tools, and brain health research alongside GBHI partnership.
• Brain Capital AlliancemajorStrategic or Co-development Partner · 1 January 2022Public-private alliance led by Harris Eyre for brain health policy and innovation agenda, in collaboration with OECD Neuroscience Policy Initiative.
• Hospital del Salvador Memory UnitminorStrategic or Co-development Partner · 1 January 2022Collaboration on neuroscience and public policy courses, alongside BrainLat and IDB.
• Walking The Talk For Dementia (CDD)minorStrategic or Co-development Partner · 1 January 2022Participation in pilgrimage walking project to Santiago de Compostela to raise dementia awareness, including scientific symposium and documentary.
• Ireland Embassy in ChileminorStrategic or Co-development Partner · 1 January 2021Collaboration through Ireland-Chile research partnerships campaign, including interview with Irish Ambassador Paul Gleeson on GBHI-BrainLat collaboration.
• Global Brain Health Institute (GBHI)coreStrategic or Co-development Partner · 1 January 2020Flagship partnership with GBHI at University of California San Francisco (UCSF) and Trinity College Dublin (TCD). Collaboration includes joint research initiatives, training fellowships, and the ReDLat consortium. GBHI co-directors Ian Robertson and Brian Lawlor actively collaborate with BrainLat leadership.
• ReDLat ConsortiumcoreStrategic or Co-development Partner · 1 January 2020One of the largest dementia research initiatives in Latin America, financed by the US National Institutes of Health (NIH). Connects researchers across Latin America and US Latino populations for neurodegenerative disease research.
• Universidad de Chile / CMYNcoreStrategic or Co-development Partner · 1 January 2020Collaboration with Memory and Neuropsychiatry Clinic (CMYN) at Universidad de Chile for joint research on neurodegeneration and brain health.
• Universidad de San Andrés / CSCNmajorStrategic or Co-development Partner · 1 January 2020Cognitive neuroscience center collaboration, including Consciousness, Culture and Complexity Lab, for social cognitive neuroscience research.
• Universidad Adolfo Ibáñez (UAI) SchoolscoreStrategic or Co-development Partner · 1 January 2020Internal collaboration across School of Psychology, Faculty of Engineering and Science, School of Government, and School of Business at Universidad Adolfo Ibáñez.
• Alzheimer's Association / ISTAARTcoreStrategic or Co-development Partner · 1 January 2020Partnership for AAIC conferences, ISTAART webinars, neuroscience next hubs, and global dementia research initiatives.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cambridge Cognition: Digital cognitive assessment and neuropsychology technology company supplying clinical trials and research — directly comparable to BrainLat's cognitive evaluation and brain health measurement product line.
• Cogstate: Computerized cognitive testing and digital brain health platform widely used in clinical trials and healthcare — comparable to BrainLat's Neureka LATAM mobile self-administered neurocognitive assessment offering.
• Altoida: Digital neurocognitive assessment platform using AI/AR on mobile devices to detect early signs of cognitive impairment — listed as a technology collaborator on BrainLat's Neureka LATAM project, indicating overlapping product approach.
• Global Brain Health Institute (GBHI): GBHI at UCSF and Trinity College Dublin is BrainLat's flagship international partner and the most directly comparable peer — an academic brain health/dementia research organization focused on training leaders, with overlapping faculty and consortia.
• GERO: AI-driven aging biomarker platform using biological age clocks and longitudinal data — listed as a technology collaborator on Neureka LATAM and shares BMindTune's 'aging clock' scientific underpinnings.
• Linus Health: Digital cognitive assessment and brain health platform combining AI with traditional neuropsychological testing for early detection of impairment — directly comparable to BMindTune/Neureka's consumer-facing brain aging and cognitive assessment product.

Others

• Alzheimer's Drug Discovery Foundation: Foundation that funds and accelerates Alzheimer's/dementia drug development — listed as a direct funding partner of BrainLat. Adjacent rather than competing; comparable from a research-funding and translational lens.

Broad incumbents

• Alzheimer's Association: The largest global advocacy and research organization for dementia/Alzheimer's, with which BrainLat partners via ISTAART and AAIC. Incumbent in the same mission space but operates at much larger scale with advocacy rather than research focus.
• Rush Alzheimer's Disease Center: One of the leading US-based NIH-funded dementia research centers with longitudinal cohorts and biomarker programs. Comparable academic research scope (publishing in Nature-tier journals, multi-cohort biomarker validation) at much larger scale.
• UCSF Memory and Aging Center: Major US dementia/neurodegeneration research center that co-hosts GBHI and has active research collaborations with BrainLat's leadership — comparable academically but far larger in funding, faculty, and clinical footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/BrainlatUAI
• YouTubeyoutube.com/channel/UCbfBRvwAp_KQJFvIcA69nug
• Facebookfacebook.com/BrainLat-UAI-100959325409263
• LinkedInlinkedin.com/company/brainlat-uai
• Instagraminstagram.com/brainlatuai

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainLat UAI